As of 2026-03-29, the Relative Valuation of Cogent Biosciences Inc (COGT) is (46.92) USD. This relative valuation is based on P/E multiples. With the latest stock price at 36.10 USD, the upside of Cogent Biosciences Inc based on Relative Valuation is -230.0%.
The range of the Relative Valuation is (45.19) - (50.46) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.3x - 26.4x | 24.4x |
| Forward P/E multiples | 20.8x - 24.9x | 21.9x |
| Fair Price | (45.19) - (50.46) | (46.92) |
| Upside | -225.2% - -239.8% | -230.0% |
| Date | P/E |
| 2026-03-25 | -18.01 |
| 2026-03-24 | -17.25 |
| 2026-03-23 | -17.47 |
| 2026-03-20 | -16.47 |
| 2026-03-19 | -17.08 |
| 2026-03-18 | -16.96 |
| 2026-03-17 | -17.48 |
| 2026-03-16 | -17.61 |
| 2026-03-13 | -16.78 |
| 2026-03-12 | -17.43 |
| 2026-03-11 | -17.80 |
| 2026-03-10 | -18.10 |
| 2026-03-09 | -18.26 |
| 2026-03-06 | -18.30 |
| 2026-03-05 | -18.48 |
| 2026-03-04 | -18.27 |
| 2026-03-03 | -18.38 |
| 2026-03-02 | -19.19 |
| 2026-02-27 | -19.17 |
| 2026-02-26 | -19.47 |
| 2026-02-25 | -19.72 |
| 2026-02-24 | -19.33 |
| 2026-02-23 | -18.29 |
| 2026-02-20 | -18.42 |
| 2026-02-19 | -18.92 |
| 2026-02-18 | -18.92 |
| 2026-02-17 | -18.56 |
| 2026-02-13 | -18.03 |
| 2026-02-12 | -18.12 |
| 2026-02-11 | -18.36 |
| 2026-02-10 | -18.64 |
| 2026-02-09 | -18.73 |
| 2026-02-06 | -18.30 |
| 2026-02-05 | -17.62 |
| 2026-02-04 | -18.18 |
| 2026-02-03 | -18.40 |
| 2026-02-02 | -18.73 |
| 2026-01-30 | -17.72 |
| 2026-01-29 | -18.58 |
| 2026-01-28 | -18.93 |
| 2026-01-27 | -19.00 |
| 2026-01-26 | -18.68 |
| 2026-01-23 | -18.10 |
| 2026-01-22 | -19.51 |
| 2026-01-21 | -19.69 |
| 2026-01-20 | -19.69 |
| 2026-01-16 | -19.21 |
| 2026-01-15 | -19.37 |
| 2026-01-14 | -18.65 |
| 2026-01-13 | -17.41 |